NO20024270L - Vedvarende frigivelsesranolazinformuleringer - Google Patents

Vedvarende frigivelsesranolazinformuleringer

Info

Publication number
NO20024270L
NO20024270L NO20024270A NO20024270A NO20024270L NO 20024270 L NO20024270 L NO 20024270L NO 20024270 A NO20024270 A NO 20024270A NO 20024270 A NO20024270 A NO 20024270A NO 20024270 L NO20024270 L NO 20024270L
Authority
NO
Norway
Prior art keywords
sustained release
release ranolazine
ranolazine formulations
formulations
sustained
Prior art date
Application number
NO20024270A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024270D0 (no
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24074628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024270(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20024270D0 publication Critical patent/NO20024270D0/no
Publication of NO20024270L publication Critical patent/NO20024270L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20024270A 2000-03-08 2002-09-06 Vedvarende frigivelsesranolazinformuleringer NO20024270L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/520,932 US6479496B1 (en) 1998-09-10 2000-03-08 Methods for treating angina with ranolazine
PCT/US2001/007287 WO2001066093A2 (en) 2000-03-08 2001-03-07 Sustained release ranolazine formulations

Publications (2)

Publication Number Publication Date
NO20024270D0 NO20024270D0 (no) 2002-09-06
NO20024270L true NO20024270L (no) 2002-11-06

Family

ID=24074628

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024270A NO20024270L (no) 2000-03-08 2002-09-06 Vedvarende frigivelsesranolazinformuleringer

Country Status (17)

Country Link
US (1) US6479496B1 (sl)
EP (1) EP1263439A2 (sl)
JP (2) JP4108980B2 (sl)
CN (1) CN1323664C (sl)
AU (3) AU4009201A (sl)
BR (1) BR0109091A (sl)
CA (1) CA2402222C (sl)
CZ (1) CZ20022996A3 (sl)
HK (1) HK1058003A1 (sl)
HU (1) HUP0204409A3 (sl)
IL (1) IL151575A0 (sl)
MX (1) MXPA02008654A (sl)
NO (1) NO20024270L (sl)
NZ (1) NZ521292A (sl)
PL (1) PL357273A1 (sl)
RU (1) RU2002126615A (sl)
WO (1) WO2001066093A2 (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648407A4 (en) 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (en) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN100455288C (zh) * 2006-06-26 2009-01-28 哈药集团制药总厂 一种盐酸雷诺嗪制剂配方
US20080031949A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0721741A2 (pt) * 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
AU2009212254A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
NO3175985T3 (sl) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
EP0714660B1 (en) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物

Also Published As

Publication number Publication date
CA2402222A1 (en) 2001-09-13
CA2402222C (en) 2009-11-03
CN1323664C (zh) 2007-07-04
BR0109091A (pt) 2005-02-15
MXPA02008654A (es) 2004-09-06
HUP0204409A3 (en) 2005-04-28
AU2001240092B8 (en) 2004-12-02
HUP0204409A2 (en) 2003-05-28
EP1263439A2 (en) 2002-12-11
IL151575A0 (en) 2003-04-10
NZ521292A (en) 2008-07-31
AU2008212005A1 (en) 2008-09-25
CZ20022996A3 (cs) 2003-09-17
JP2008069159A (ja) 2008-03-27
AU2001240092B2 (en) 2004-10-14
CN1443069A (zh) 2003-09-17
PL357273A1 (en) 2004-07-26
WO2001066093A3 (en) 2002-03-14
RU2002126615A (ru) 2004-03-20
NO20024270D0 (no) 2002-09-06
AU4009201A (en) 2001-09-17
HK1058003A1 (en) 2004-04-30
WO2001066093A2 (en) 2001-09-13
JP2003525896A (ja) 2003-09-02
JP4108980B2 (ja) 2008-06-25
US6479496B1 (en) 2002-11-12

Similar Documents

Publication Publication Date Title
NO20024270L (no) Vedvarende frigivelsesranolazinformuleringer
DK1096937T3 (da) Ranolazinformuleringer med langvarig frigivelse
DK1317177T3 (da) Desinficerende formuleringer
NO20031483L (no) Vaksine
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
NO20024172L (no) Vaksine
DE60128599D1 (de) Arbeitsgerät
ATA2932001A (de) Schneefräse
ATE262530T1 (de) Indolochinazolinone
DE60033666D1 (de) Verstärker
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE10196064T1 (de) Halbleiterfotodektionsgerät
ATE268116T1 (de) Mesotrion-formulierungen
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone
ATA7092001A (de) Skibindungseinstellgerät

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application